uniQure N.V. (QURE)
Automate Your Wheel Strategy on QURE
With Tiblio's Option Bot, you can configure your own wheel strategy including QURE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QURE
- Rev/Share 0.3804
- Book/Share 0.6343
- PB 23.4919
- Debt/Equity 1.9651
- CurrentRatio 11.9918
- ROIC -0.3034
- MktCap 815752650.0
- FreeCF/Share -3.1524
- PFCF -4.8724
- PE -3.6371
- Debt/Assets 0.1093
- DivYield 0
- ROE -4.8387
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | QURE | Chardan Capital Markets | -- | Buy | -- | $38 | April 1, 2025 |
| Upgrade | QURE | Raymond James | Outperform | Strong Buy | -- | -- | Dec. 10, 2024 |
| Resumed | QURE | Raymond James | -- | Outperform | -- | $20 | Oct. 10, 2024 |
News
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Read More
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Read More
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 161.5% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
UniQure (QURE) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.36 per share a year ago.
Read More
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of …
Read More
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here.
Read More
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.
Read More
uniQure N.V.: A Potential Huntington's Play
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.
Read More
About uniQure N.V. (QURE)
- IPO Date 2014-02-05
- Website https://www.uniqure.com
- Industry Biotechnology
- CEO Mr. Matthew Craig Kapusta CPA
- Employees 209